Importantly, dual inhibition of PTPN1/N2 markedly enhances the cytolytic activity of cord blood NK cells against patient-derived glioblastoma cells, highlighting the potential of this approach for future therapeutic applications. Here, PTPN1 is linked to glioblastoma.